180 Life Sciences Granted European Patent EP3265107 For Treating Dupuytren's Disease Using TNF Receptor 2 Antagonist
Portfolio Pulse from Benzinga Newsdesk
180 Life Sciences has been granted a European patent for treating Dupuytren's Disease using a TNF Receptor 2 antagonist. This development could enhance their intellectual property portfolio and potentially lead to new treatment options.
September 04, 2024 | 7:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
180 Life Sciences has received a European patent for a treatment method for Dupuytren's Disease, which could strengthen its intellectual property and open new market opportunities.
The granting of a European patent is a significant milestone for 180 Life Sciences, as it not only strengthens their intellectual property portfolio but also potentially opens up new markets in Europe. This could lead to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90